Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD
Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD: Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: ahmed alanwar, MD
- Phone Number: +201111486669
- Email: eladwar@hotmail.com
Study Locations
-
-
-
Cairo, Egypt, 11331
- Recruiting
- Ahmed Alanwar
-
Contact:
- ahmed alanwar, MD
- Phone Number: 002 +201111486669
- Email: eladwar@hotmail.com
-
Contact:
- ahmed kotb, MD
- Phone Number: 002 +201008681999
- Email: ahmedmkotp@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women complaining from an menorrhagia secondary to a current copper IUD use.
- Age: 20-40years.
- Menorrhagia , will be defined as a PBAC-Score greater than 100.
- No systemic causes of abnormal uterine bleeding as hypertension and hemorrhagic blood diseases.
- No other local causes of abnormal uterine bleeding as, (fibroid, adenomyosis, polyps).
- No drugs decreasing blood coagulation.
- Well fitted IUD not misplaced.
Exclusion Criteria:
- Age <20y and >40y.
- Irregular menstrual cycle.
- Presence of systemic causes of abnormal uterine bleeding as hypertension and hemorrhagic blood diseases.
- Presence of other local causes of abnormal uterine bleeding as, (fibroid, adenomyosis, polyps).
- Taking drugs decrease blood coagulation.
- Misplaced IUD.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Tranexamic acid
|
use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC
Other Names:
|
|
Active Comparator: Diosmin
|
use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then
The amount of menstrual flow will be calculated by the PBAC
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The amount of reducing heavy menstrual flow will be calculated by the PBAC.
Time Frame: the first 24hours
|
measure the bleeding rate will be by the pictorial blood assessment chart (PBAC).
|
the first 24hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TXAvsDiosmin-IUDmenorrhagia
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.